Bioverge

Bioverge is a platform that gives accredited investors access to early-stage healthcare, biotech, and medtech startups — a sector that represents a significant portion of U.S. venture capital but has historically been dominated by specialized institutional funds and family offices. The platform curates a narrow list of deals each year, focusing on companies at seed or Series A stages that are developing novel therapeutics, diagnostic tools, medical devices, or digital health infrastructure. The deal flow is intentionally selective compared to generalist platforms like AngelList or Republic — Bioverge's team reviews hundreds of opportunities and typically presents only a small handful to members for investment.

The platform's value proposition is deep domain expertise. Bioverge's leadership includes professionals with backgrounds in healthcare investing, clinical medicine, and scientific due diligence, which translates into more rigorous vetting than most generalist crowdfunding platforms offer. Investors gain access to deals alongside institutional co-investors and can invest through individual SPVs or occasional fund vehicles. Minimums typically start at $10,000 per deal, and most offerings close within 60–90 days of being opened to the Bioverge network.